Immatics (NASDAQ:IMTXW) Stock Price Up 1.3%

Immatics (NASDAQ:IMTXWGet Free Report)’s stock price traded up 1.3% during mid-day trading on Wednesday . The company traded as high as $3.25 and last traded at $3.15. 1,380 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 4,431 shares. The stock had previously closed at $3.11.

Immatics Price Performance

The stock has a fifty day moving average price of $3.47 and a 200-day moving average price of $3.03.

Institutional Trading of Immatics

A number of hedge funds have recently modified their holdings of IMTXW. Virtu Financial LLC purchased a new position in Immatics during the fourth quarter worth approximately $28,000. Jefferies Financial Group Inc. purchased a new position in Immatics during the fourth quarter worth approximately $80,000. Alyeska Investment Group L.P. purchased a new position in Immatics during the fourth quarter worth approximately $529,000. Walleye Capital LLC boosted its position in Immatics by 25.7% during the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock worth $889,000 after purchasing an additional 53,153 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Immatics by 11.9% during the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock worth $1,293,000 after purchasing an additional 40,168 shares in the last quarter.

Immatics Company Profile

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

See Also

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.